Vemlidy — Total revenues
Gilead Sciences Vemlidy — Total revenues decreased by 17.1% to $237.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 6.0%, from $252.00M to $237.00M. Over 3 years (FY 2022 to FY 2025), Vemlidy — Total revenues shows an upward trend with a 8.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase in revenue indicates strong market penetration, successful patient retention, or expanded clinical adoption of the therapy. A decrease may signal increased competition from generics, loss of patent exclusivity, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total gross revenue generated from the sales of a specific pharmaceutical product within the...
Peer comparison
Comparable to product-specific revenue lines reported by other biopharmaceutical companies, such as branded drug sales in oncology or immunology segments.
gild_segment_vemlidy_total_revenuesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $210.50M | $210.50M | $210.50M | $210.50M | $215.50M | $215.50M | $215.50M | $215.50M | $225.00M | $243.00M | $232.00M | $259.00M | $252.00M | $252.00M | $280.00M | $286.00M | $237.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +2.4% | +0.0% | +0.0% | +0.0% | +4.4% | +8.0% | -4.5% | +11.6% | -2.7% | +0.0% | +11.1% | +2.1% | -17.1% |
| YoY Change | — | — | — | — | +2.4% | +2.4% | +2.4% | +2.4% | +4.4% | +12.8% | +7.7% | +20.2% | +12.0% | +3.7% | +20.7% | +10.4% | -6.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's vemlidy — total revenues?
- Gilead Sciences (GILD) reported vemlidy — total revenues of $237.00M in Q1 2026.
- How has Gilead Sciences's vemlidy — total revenues changed year-over-year?
- Gilead Sciences's vemlidy — total revenues decreased by 6.0% year-over-year, from $252.00M to $237.00M.
- What is the long-term trend for Gilead Sciences's vemlidy — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's vemlidy — total revenues has grown at a 8.3% compound annual growth rate (CAGR), from $842.00M to $1.07B.
- What does vemlidy — total revenues mean?
- The total sales revenue generated by the specific liver disease medication Vemlidy.